Stelara 90MG/ML SYR 1S
Ended Awarded
- Contract number
- SPE2DR26FBTAR
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $82,921
Award facts
- Contract value 100% obligated
- $82,920.65 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $82,920.65 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90mg/mL syringes. This firm fixed-price delivery order, issued on October 24, 2025, represents one of numerous pharmaceutical supply orders placed with DMS Pharmaceutical Group under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The delivery order carries an ultimate completion date of November 21, 2025, with no set-aside designation applied. DMS Pharmaceutical Group will perform the work at its headquarters location in Park Ridge, Illinois.
This delivery order is issued under DMS Pharmaceutical Group's broader indefinite delivery contract (IDC) with the DLA, a single-award contract valued at $499.999 billion through December 31, 2036, that positions the company as a critical pharmaceutical supplier for Department of Defense healthcare operations globally. The PPV-G GEN V program, a $30.3 billion federal acquisition strategy, establishes multiple regional prime vendor contractors to provide comprehensive pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through consistent performance on numerous delivery orders across diverse therapeutic categories, including specialty biologics such as Stelara, oncology treatments, vaccines, and emergency medications.
Quick answers
Who was awarded contract SPE2DR26FBTAR?
SPE2DR26FBTAR was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 24, 2025.
How much is contract SPE2DR26FBTAR worth?
The government has obligated $82,921 on SPE2DR26FBTAR.
Is contract SPE2DR26FBTAR an order under another contract?
Yes. SPE2DR26FBTAR is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTAR competed?
The extent of competition for SPE2DR26FBTAR was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award